Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: CLEOPATRA trial | Statement: [Perjeta, clinicalTrial, CLEOPATRA trial]

Target entity: CLEOPATRA trial
Context triple: [Perjeta, clinicalTrial, CLEOPATRA trial]

• A. ENSEMBLE trial
  The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
• B. EMERGE (Study 302)
  EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
• C. CAPTOR-E
  CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
• D. ENGAGE (Study 301)
  ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
• E. RuSHA Trial
  The RuSHA Trial was one of the Subsequent Nuremberg Trials in which SS officials were prosecuted for implementing Nazi racial policies, including forced resettlement, kidnapping of children, and persecution based on racial criteria.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: CLEOPATRA trial
Triple: [Perjeta, clinicalTrial, CLEOPATRA trial]

The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.

Target entity: CLEOPATRA trial
Target entity description: The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.

• A. ENSEMBLE trial
  The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
• B. EMERGE (Study 302)
  EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
• C. CAPTOR-E
  CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
• D. ENGAGE (Study 301)
  ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
• E. RuSHA Trial
  The RuSHA Trial was one of the Subsequent Nuremberg Trials in which SS officials were prosecuted for implementing Nazi racial policies, including forced resettlement, kidnapping of children, and persecution based on racial criteria.
• F. None of above. chosen